Biofocus and AstraZeneca Enter Drug Discovery Collaboration

The total contract value for Galapagos is 620,000 euro.
"Extending our existing partnership and securing further projects with AstraZeneca is a high priority for us,” said Onno van de Stolpe, CEO of Galapagos. "This latest collaboration demonstrates the positive working relationship and establishes our position as a proven partner specialized in drug discovery services.”

"BioFocus DPI's commitment to delivering projects of high quality and on time has been the main driver of AstraZeneca's decision to enter into a new agreement with BioFocus DPI. We have been pleased with the level of progress thus far and expect that BioFocus DPI's expanded ADMET and predictive drug discovery capabilities will be key contributors in advancing this hit-to-lead program,” added Dr. Lars-Erik Arvidsson, vice president R&D Lund, AstraZeneca.

Galapagos is a drug discovery company with clinical and pre-clinical programs in bone and joint diseases, cachexia, and menopausal hot flashes. Its division BioFocus DPI offers a full range of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening, as well as chemogenomics and ADMET1 database products to select targets and compounds.


Related Links:
BioFocus DPI
Galapagos
AstraZeneca